With reference to its letter dated January 17, 2019 informing about entering into a definitive agreement to acquire seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc., (NASDAQ:SPPI), a US based global branded oncology company by Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is a wholly owned subsidiary of the Company. In this regard, Aurobindo Pharma has informed that the aforesaid acquisition has been completed on March 1, 2019.
The above information is a part of company’s filings submitted to BSE.
